Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics (Nasdaq: MCRB) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. President and CEO Eric Shaff will engage in a fireside chat on December 3, 2024, at 4:30 p.m. ET. The event will be accessible via live webcast through the company's website under the 'Events and Presentations' tab in the 'Investors and News' section, with replay available after the event.
Seres Therapeutics (Nasdaq: MCRB) ha annunciato la sua partecipazione alla 36陋 Conferenza Sanitaria Annuale di Piper Sandler. Il Presidente e CEO Eric Shaff parteciper脿 a una chiacchierata informale il 3 dicembre 2024, alle 16:30 ET. L'evento sar脿 accessibile tramite webcast dal vivo dal sito web dell'azienda nella sezione 'Eventi e Presentazioni' sotto 'Investitori e Notizie', con registrazione disponibile dopo l'evento.
Seres Therapeutics (Nasdaq: MCRB) ha anunciado su participaci贸n en la 36陋 Conferencia Anual de Salud de Piper Sandler. El Presidente y CEO Eric Shaff participar谩 en una charla informal el 3 de diciembre de 2024, a las 4:30 p.m. ET. El evento estar谩 disponible a trav茅s de una transmisi贸n en vivo en el sitio web de la empresa en la secci贸n 'Eventos y Presentaciones' bajo 'Inversores y Noticias', con una repetici贸n disponible despu茅s del evento.
靹鸽爤鞀� 韰岆澕頁嫳鞀� (Nasdaq: MCRB)電� 韺岇澊韻� 靸岆摛霟� 鞝�36須� 鞐半 瓯搓皶 須岇潣鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 靷灔 瓴� CEO 鞐愲Ν 靸ろ攧臧� 2024雲� 12鞗� 3鞚� 鞓ろ泟 4鞁� 30攵� ET鞐� 歆勴枆霅橂姅 雽�頇旍棎 彀胳棳頃╇媹雼�. 鞚� 頄夓偓電� 須岇偓 鞗轨偓鞚错姼鞚� '鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴' 韮� 鞎勲灅 '韴瀽鞛� 氚� 雺挫姢' 靹轨厴鞐愳劀 鞁れ嫓臧� 鞗轨簮鞀ろ姼毳� 韱淀暣 鞝戧芳頃� 靾� 鞛堨溂氅�, 頄夓偓 頉� 鞛儩鞚� 臧�電ロ暕雼堧嫟.
Seres Therapeutics (Nasdaq: MCRB) a annonc茅 sa participation 脿 la 36猫me Conf茅rence Annuelle de Sant茅 de Piper Sandler. Le Pr茅sident et CEO Eric Shaff participera 脿 une discussion informelle le 3 d茅cembre 2024 脿 16h30 ET. L'茅v茅nement sera accessible via un webcast en direct sur le site de l'entreprise dans l'onglet '脡v茅nements et Pr茅sentations' sous 'Investisseurs et Actualit茅s', avec une rediffusion disponible apr猫s l'茅v茅nement.
Seres Therapeutics (Nasdaq: MCRB) hat seine Teilnahme an der 36. j盲hrlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Pr盲sident und CEO Eric Shaff wird am 3. Dezember 2024 um 16:30 Uhr ET an einem Gespr盲ch teilnehmen. Die Veranstaltung wird 眉ber einen Live-Webcast auf der Website des Unternehmens unter dem Tab 'Veranstaltungen und Pr盲sentationen' im Bereich 'Investoren und Nachrichten' zug盲nglich sein, mit einer Wiederholung, die nach der Veranstaltung verf眉gbar sein wird.
- None.
- None.
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.
A live webcast of the chat will be accessible through the 鈥淓vents and Presentations鈥� tab on the 鈥淚nvestors and News鈥� section of the Company鈥檚 website at and will be available for replay following the event.
About聽Seres Therapeutics
Seres Therapeutics, Inc.聽(Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST鈩�, the first FDA-approved orally administered microbiome therapeutic, and which was sold to Nestl茅 Health Science in聽September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections聽and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit聽.
Investor and Media Contacts:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
This press release was published by a CLEAR庐 Verified individual.
FAQ
When is Seres Therapeutics (MCRB) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Seres Therapeutics (MCRB) fireside chat at the Piper Sandler Conference?
Will there be a replay available of Seres Therapeutics (MCRB) Piper Sandler Conference presentation?
